Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

NCT02014649 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated as per BARDA decision to terminate contract.

Conditions

Influenza

Interventions

DRUG: 20 mg laninamivir octanoate
DRUG: Placebo
DRUG: 40 mg laninamivir octanoate

Sponsor

Biota Scientific Management Pty Ltd

Collaborators

[object Object]